Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Fudan University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
68High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07079436CT.gov EIT Evaluation of Pulmonary Ventilation With Different Ropivacaine Concentrations in Intercostal Nerve Blockade | — | Not Yet Recruiting | — | — | — |
NCT06608810CT.gov The Application of Pectoral Nerve II(PECS II)block in Breast Fibroadenoma Resection Surgery | — | Completed | — | — | — |
NCT04827030CT.gov ER-One: A Double-blind Trial of Erector Spinae Block (ESP) Versus Paravertebral Block (PVB) Before Breast Cancer Surgery | — | Completed | — | — | — |
NCT03117894CT.gov PECS-2 for Breast Surgery | — | Completed | — | — | — |
NCT02655965CT.gov Double-blind Study to Assess effectIveness of Pectoral Nerves Block After Breast Surgery on Piritramide Consumption | — | Completed | — | — | — |
NCT00370240CT.gov Chlorhydrate of Ropivacaine and Breast Cancer Surgery | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ropivacaine (this asset) | Fudan University | Approved | BB · 67 |
| Docetaxel | Universitas Airlangga | P4 | BB |
| Letrozole | Fujian Cancer Hospital | P4 | BB |
| Tamoxifen | Eli Lilly and Company | P3 | BB |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P4 | BB |
| Adriamycin | Merck Sharp & Dohme LLC | P4 | BB |
| Exemestane | Fujian Cancer Hospital | P4 | BB |
| Epirubicin | Universitas Airlangga | P4 | BB |
| Microporous Polysaccharide Hemospheres | Fundación para la Investigación del Hospital Clínico de Valencia | P4 | BB |
+42 more in the Breast Neoplasm cohort
Other indications for Ropivacaine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Osteoarthritis, Hip | — | P4 | BBB · 76 |
| Post-Operative Pain, Non-Human Animal | — | P4 | BBB · 76 |
| Cerebral Palsy | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ropivacaine in Breast Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ropivacaine-breast-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →